Serina Therapeutics advances SER-252 to Cohort 2
Serina Therapeutics said its Independent Safety Monitoring Committee cleared SER-252 to move to Cohort 2 after blinded Cohort 1 showed sustained apomorphine exposure and encouraging motor improvements.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.